At a glance
- Originator Medea Research; SIR International
- Class Anti-inflammatories; Cardiotonics; Class III antiarrhythmics
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 21 Oct 1997 Discontinued - Preclinical for Arrhythmias (Unknown route)
- 04 Apr 1997 No-Development-Reported for Arrhythmias (Unknown route)
- 09 Dec 1994 Preclinical development for Arrhythmias (Unknown route)